Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004918 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00004918: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004918 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004918, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Vaccines made from peptides that are found on leukemia cells may make the body build an immune response and kill cancer cells. Combining vaccine therapy with the immune adjuvant Montanide ISA-51 may be a more effective treatment for chronic myeloid leukemia, acute myeloid leukemia, or myelodysplastic syndrome. This phase I/II trial is studying the side effects and best dose of vaccine therapy when given with Montanide ISA-51 and to see how well they work in treating patients with chronic myeloid leukemia, acute myeloid leukemia, or myelodysplastic syndrome
Interventions
- OTHER laboratory biomarker analysis
- DRUG Montanide ISA 51 VG
- BIOLOGICAL sargramostim
- BIOLOGICAL PR1 leukemia peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 1999-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004918
The ClinicalTrials.gov registry entry for NCT00004918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00004918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004918 about?
NCT00004918 is a clinical study titled "Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome". Vaccines made from peptides that are found on leukemia cells may make the body build an immune response and kill cancer cells. Combining vaccine therapy with the immune adjuvant Montanide ISA-51 may be a more effective treatment for chronic myeloid leukemia, acute myeloid leukemia, or myelodysplasti...
What is the current status of trial NCT00004918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 1999-12.
What interventions are being tested in trial NCT00004918?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Montanide ISA 51 VG (DRUG), sargramostim (BIOLOGICAL), PR1 leukemia peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004918?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.